Prototype Drug Unit 5 & 7- Cyclobenzaprine

Question 1

Therapeutic classification

Answer 1

Skeletal muscle relaxant

Question 2

Pharmacologic classification

Answer 2

Centrally acting antispasmodic

Question 3

Therapeutic effects and uses

Answer 3

Short-term therapy for acute musculoskeletal conditions. Promotes skeletal muscle relaxation, thus decreasing muscle spasms and increasing joint mobility.

Question 4

Mechanism of Action

Answer 4

Increases norepinephrine activity by blocking its synaptic reuptake to produce an anticholinergic effect.

Question 5

Adverse effects

Answer 5

Drowsiness, xerostomia, dizziness, fatigue, nausea, constipation, dyspepsia

Question 6

Contraindications

Answer 6

Don’t give it to people who are hypersensitive, who have QT interval prolongation on the electrocardiogram, or who are in the recovery phase of myocardial infarction, patients who have a history of hyperthyroidism. Use with caution on patients who have liver problems, cardiovascular disease, over the age of 65, intraocular pressure, prostatic hyperplasia, urinary retention, and seizures.

Question 7

Drug interactions

Answer 7

Alcohol, opoids, barbiturates, or other CNS depressants. Phenothiazines and anticholinergics. Contraindicated with cyclobenzaprine. TCAs create additive CNS depression. Do not use withing 14 days of an MAOI.

Question 8

Herbal/food interactions

Answer 8

Valerian or kava causes additive CNS depression

Question 9

Treatment of overdose

Answer 9

Physosotigmine may be given to reverse serious anticholinergic effects